2025-01-16 02:45:36 pm | Source: Motilal Oswal Financial Services Ltd
Neutral Cipla Ltd For Target Rs. 1,550 by Motilal Oswal Financial Services Ltd
* US sales to decline 4% YoY to USD220m for 3QFY25 led by price erosion and temporary lower off-take of Lanreotide.
* Expect DF sales to grow 7% YoY, driven by stronger growth in cardiac/gastro/urology, market share gain, and inlicensing opportunities.
* USFDA regulatory outlook at Pithampur facility.
* Progress on inhalation/peptide assets for the US generic market and Semaglutide for the Indian market.
For More Research Reports : Click Here
For More Motilal Oswal Securities Ltd Disclaimer
http://www.motilaloswal.com/MOSLdisclaimer/disclaimer.html
SEBI Registration number is INH000000412
Disclaimer:
The content of this article is for informational purposes only and should not be considered financial or
investment advice. Investments in financial markets are subject to market risks, and past performance is
not indicative of future results. Readers are strongly advised to consult a licensed financial expert or
advisor for tailored advice before making any investment decisions. The data and information presented
in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the
content of this article for any current or future financial references.
To Read Complete Disclaimer Click Here
Latest News
?Self-reliant but not immune??: Ex-diplomat Mahesh S...
BJP leader Pallab Lochan Das hails PM Narendra Modi ...
Chirag Paswan on Special Session for Women?s Reserva...
Quote on expectations from the upcoming RBI MPC anno...
.jpg)
Gas shortage hits auto-rickshaw drivers across Benga...
Government eyes boost in production of induction hea...
Government okays Rs 132.51 crore for connectivity pr...
Rupee depreciation post Feb 27 in line with other cu...
Sentiment on Indian IT sector turns bearish amid glo...
Maruti Suzuki expands service network to 5,926 touch...
